Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors Following Announcement of Update from Bristol-Myers Squibb and Nektar on the PIVOT-IO-001 Phase 3 Trial

Rhea-AI Summary

Nektar Therapeutics (NASDAQ:NKTR) is hosting a conference call for analysts and investors on March 14, 2022, at 5:00 a.m. PST. This follows an update from Bristol-Myers Squibb and Nektar regarding the pivotal Phase 3 PIVOT IO-001 study focused on unresectable or metastatic melanoma. The call will be accessible via Nektar's investor relations website and will be available for replay until April 15, 2022.

Positive

• Nektar is advancing its pivotal Phase 3 PIVOT IO-001 study in melanoma.
• The conference call demonstrates Nektar's transparency with investors.

Negative

• The outcomes of the PIVOT IO-001 study remain to be disclosed, introducing uncertainty.

SAN FRANCISCO, March 14, 2022 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) will hold an analyst and investor conference call with Nektar management today, Monday, March 14, 2022, at 5:00 a.m. Pacific Standard Time (PST), following this morning's update from Bristol-Myers Squibb and Nektar on the pivotal Phase 3 PIVOT IO-001 study in previously untreated unresectable or metastatic melanoma.

The press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: http://ir.nektar.com/. The web broadcast of the conference call will be available for replay through April 15, 2022.

To access the conference call, follow these instructions:

Dial: (877) 881-2183 (U.S); (970) 315-0453 (international)
Conference ID: 9853125 (Nektar Therapeutics is the host)

About Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company with a robust, wholly owned R&D pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

Contact:

For Investors:
Vivian Wu of Nektar Therapeutics
628-895-0661

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-therapeutics-to-host-webcast-conference-call-for-analysts--investors-following-announcement-of-update-from-bristol-myers-squibb-and-nektar-on-the-pivot-io-001-phase-3-trial-301501589.html

SOURCE Nektar Therapeutics

FAQ

What is the purpose of the PIVOT IO-001 study by Nektar Therapeutics?

The PIVOT IO-001 study is a pivotal Phase 3 trial focused on treating previously untreated unresectable or metastatic melanoma.

When will Nektar Therapeutics host the conference call regarding its Phase 3 study?

The conference call will be held on March 14, 2022, at 5:00 a.m. PST.

How can I access the Nektar Therapeutics conference call?

The conference call can be accessed by dialing (877) 881-2183 within the U.S. or (970) 315-0453 internationally, using conference ID 9853125.

What is the significance of Bristol-Myers Squibb's update related to the PIVOT IO-001 study?

Bristol-Myers Squibb's update is crucial as it provides essential insights and data that could impact the development of Nektar's treatment for melanoma.

Until when will the conference call replay be available?

The replay will be available until April 15, 2022.